| A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer (NCT03499899) | Novartis Pharmaceuticals | 2018-07-02 |
| Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis (NCT03504852) | Novartis Pharmaceuticals | 2018-06-25 |
| LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI) (NCT03354754) | Novartis Pharmaceuticals | 2018-05-15 |
| VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib (NCT03400176) | Novartis Pharmaceuticals | 2018-04-09 |
| Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (NCT03439839) | Novartis Pharmaceuticals | 2018-04-09 |
| A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML (NCT03280030) | Novartis Pharmaceuticals | 2018-04-06 |
| Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (NCT03081234) | Novartis Pharmaceuticals | 2018-03-31 |
| Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (NCT03447769) | Novartis Pharmaceuticals | 2018-03-16 |
| Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab (NCT03249714) | Novartis Pharmaceuticals | 2018-03-15 |
| Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN) (NCT03297294) | Novartis Pharmaceuticals | 2018-03-14 |
| Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis (NCT03350815) | Novartis Pharmaceuticals | 2018-03-13 |
| Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome (NCT03440736) | Novartis Pharmaceuticals | 2018-02-28 |
| Safety Study of LLF580 in Obese Volunteers (NCT03466203) | Novartis Pharmaceuticals | 2018-02-26 |
| ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (NCT03217422) | Novartis Pharmaceuticals | 2018-02-15 |
| Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. (NCT03379727) | Novartis Pharmaceuticals | 2018-02-13 |
| Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure (NCT03387163) | Novartis Pharmaceuticals | 2018-02-09 |
| Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients (NCT03333109) | Novartis Pharmaceuticals | 2018-02-08 |
| Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation (NCT03373461) | Novartis Pharmaceuticals | 2018-02-07 |
| Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium (NCT03158311) | Novartis Pharmaceuticals | 2018-02-05 |
| Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (NCT03439046) | Novartis Pharmaceuticals | 2018-02-02 |
| Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients (NCT02939599) | Novartis Pharmaceuticals | 2018-02-01 |
| Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (NCT03301896) | Novartis Pharmaceuticals | 2018-01-31 |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (NCT03333343) | Novartis Pharmaceuticals | 2018-01-29 |
| Dabrafenib and/or Trametinib Rollover Study (NCT03340506) | Novartis Pharmaceuticals | 2018-01-26 |
| PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (NCT03365791) | Novartis Pharmaceuticals | 2018-01-24 |
| Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (NCT03372083) | Novartis Pharmaceuticals | 2018-01-16 |
| Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD (NCT03386474) | Novartis Pharmaceuticals | 2018-01-15 |
| Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH) (NCT03203850) | Novartis Pharmaceuticals | 2018-01-11 |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors (NCT02684058) | Novartis Pharmaceuticals | 2017-12-28 |
| Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH). (NCT03338998) | Novartis Pharmaceuticals | 2017-12-24 |
| Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis (NCT03287414) | Novartis Pharmaceuticals | 2017-12-20 |
| Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) (NCT03264989) | Novartis Pharmaceuticals | 2017-12-19 |
| Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma (NCT03111992) | Novartis Pharmaceuticals | 2017-12-18 |
| A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma (NCT03138811) | Novartis Pharmaceuticals | 2017-12-18 |
| Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients (NCT03369704) | Novartis Pharmaceuticals | 2017-12-15 |
| Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy (NCT03344640) | Novartis Pharmaceuticals | 2017-12-15 |
| Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis) (NCT03333694) | Novartis Pharmaceuticals | 2017-12-15 |
| A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity (NCT03320941) | Novartis Pharmaceuticals | 2017-12-07 |
| Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD) (NCT03242928) | Novartis Pharmaceuticals | 2017-12-04 |
| Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) (NCT03259074) | Novartis Pharmaceuticals | 2017-11-30 |
| First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients (NCT03355196) | Novartis Pharmaceuticals | 2017-11-20 |
| Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria. (NCT03334747) | Novartis Pharmaceuticals | 2017-11-16 |
| Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment (NCT03200717) | Novartis Pharmaceuticals | 2017-11-14 |
| Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma (NCT03299686) | Novartis Pharmaceuticals | 2017-11-06 |
| Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma (NCT03215758) | Novartis Pharmaceuticals | 2017-11-01 |
| Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma (NCT03226392) | Novartis Pharmaceuticals | 2017-10-31 |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (NCT03106779) | Novartis Pharmaceuticals | 2017-10-26 |
| Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (NCT03334812) | Novartis Pharmaceuticals | 2017-10-18 |
| Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD) (NCT02715505) | Novartis Pharmaceuticals | 2017-10-10 |
| A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment (NCT06311383) | Novartis Pharmaceuticals | 2017-10-09 |
| Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients (NCT03205150) | Novartis Pharmaceuticals | 2017-10-04 |
| A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia (NCT03025698) | Novartis Pharmaceuticals | 2017-09-30 |
| Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis (NCT02566044) | Novartis Pharmaceuticals | 2017-09-27 |
| PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer (NCT03176264) | Novartis Pharmaceuticals | 2017-09-25 |
| Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma (NCT03150160) | Novartis Pharmaceuticals | 2017-09-21 |
| Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (NCT03194776) | Novartis Pharmaceuticals | 2017-09-20 |
| A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod (NCT03257358) | Novartis Pharmaceuticals | 2017-09-19 |
| Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients (NCT02927366) | Novartis Pharmaceuticals | 2017-09-19 |
| A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (NCT03312738) | Novartis Pharmaceuticals | 2017-09-15 |
| Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis. (NCT03275064) | Novartis Pharmaceuticals | 2017-09-12 |
| Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas (NCT03172936) | Novartis Pharmaceuticals | 2017-09-08 |
| Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. (NCT03257995) | Novartis Pharmaceuticals | 2017-09-05 |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (NCT03056755) | Novartis Pharmaceuticals | 2017-08-29 |
| A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NCT03207867) | Novartis Pharmaceuticals | 2017-08-28 |
| Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone (NCT03040973) | Novartis Pharmaceuticals | 2017-08-23 |
| Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment (NCT02962414) | Novartis Pharmaceuticals | 2017-08-23 |
| A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (NCT03066804) | Novartis Pharmaceuticals | 2017-08-22 |
| A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (NCT03131453) | Novartis Pharmaceuticals | 2017-08-03 |
| Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria (NCT03167242) | Novartis Pharmaceuticals | 2017-08-02 |
| Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet (NCT02993224) | Novartis Pharmaceuticals | 2017-07-27 |
| A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder (NCT03141086) | Novartis Pharmaceuticals | 2017-07-26 |
| A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure (NCT03152552) | Novartis Pharmaceuticals | 2017-07-25 |
| Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome (NCT03152591) | Novartis Pharmaceuticals | 2017-07-24 |
| Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma (NCT02992483) | Novartis Pharmaceuticals | 2017-07-12 |
| Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (NCT03066648) | Novartis Pharmaceuticals | 2017-07-06 |
| Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects (NCT03087942) | Novartis Pharmaceuticals | 2017-07-05 |
| SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis (NCT03136861) | Novartis Pharmaceuticals | 2017-06-30 |
| Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN) (NCT03094195) | Novartis Pharmaceuticals | 2017-06-27 |
| Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS) (NCT02962895) | Novartis Pharmaceuticals | 2017-06-27 |
| Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma (NCT03108027) | Novartis Pharmaceuticals | 2017-06-26 |
| Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066 (NCT03198767) | Novartis Pharmaceuticals | 2017-06-21 |
| Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (NCT03078751) | Novartis Pharmaceuticals | 2017-06-20 |
| Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer (NCT03081494) | Novartis Pharmaceuticals | 2017-06-09 |
| A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib (NCT03050398) | Novartis Pharmaceuticals | 2017-06-07 |
| Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects (NCT03048448) | Novartis Pharmaceuticals | 2017-05-31 |
| Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (NCT03114319) | Novartis Pharmaceuticals | 2017-05-26 |
| PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (NCT03064854) | Novartis Pharmaceuticals | 2017-05-24 |
| Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) (NCT03031782) | Novartis Pharmaceuticals | 2017-05-23 |
| Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia (NCT02998645) | Novartis Pharmaceuticals | 2017-05-11 |
| A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers (NCT02452268) | Novartis Pharmaceuticals | 2017-05-08 |
| A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults (NCT03100058) | Novartis Pharmaceuticals | 2017-05-06 |
| Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma (NCT03137784) | Novartis Pharmaceuticals | 2017-05-04 |
| Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function. (NCT03131479) | Novartis Pharmaceuticals | 2017-04-28 |
| A Long-term Safety Study of QVM149 in Japanese Patients With Asthma (NCT03100825) | Novartis Pharmaceuticals | 2017-04-28 |
| An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol (NCT03060577) | Novartis Pharmaceuticals | 2017-04-27 |
| Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria (NCT03328897) | Novartis Pharmaceuticals | 2017-04-26 |
| Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NCT02947165) | Novartis Pharmaceuticals | 2017-04-25 |
| A Long-term Safety Study of QMF149 in Japanese Participants With Asthma (NCT03100500) | Novartis Pharmaceuticals | 2017-04-25 |
| Phase III B in Acute Lymphoblastic Leukemia (NCT03123939) | Novartis Pharmaceuticals | 2017-04-24 |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients (NCT02988440) | Novartis Pharmaceuticals | 2017-04-20 |